Kechao Nie

Kechao Nie

Auto-generated profile, based on publicly available information

Kechao Nie

Department of Integrated Traditional Chinese & Western Medicine The Second Xiangya Hospital, Central South University Changsha China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2026 in Food Science & Nutrition
Verified
Journal Article
Open access
PDF file
JHjiawen huang
jiawen huang
TYTian Yu
Tian Yu
GLGuoyi Li
Guoyi Li
KNKechao Nie
Kechao Nie
DLDonghua Liu
Donghua Liu
YHYing-Jie Hu
Ying-Jie Hu
Zhenyuan Solid Drink (ZYSD) is a formulation consisting of 6 medicinal herbs that can be used as both food and medicinal materials in China. This comprehensive analysis aims to illuminate the potential therapeutic effects and underlying mechanisms of ZYSD in the context of ischemic myocardial infarction. Marker components in ZYSD were identified by high performance liquid chromatography (HPLC) through comparison with reference compounds. Isoproterenol (ISO)‐induced rats were employed as the in vivo model of ischemic myocardial infarction. Subsequently, a multi‐tiered approach integrating cardiac color Doppler ultrasound, cardiac enzyme marker analysis, inflammatory factor detection, gut microbiota profiling, network pharmacology, molecular docking, molecular dynamics (MD) simulation, and western blot analysis was employed to elucidate the effects and underlying mechanisms of ZYSD, with intervention in alleviating metoprolol tartrate as positive control. Ten compounds, derived from 6 medicinal plants, in ZYSD were identified as marker components for the quality control via HPLC. Animal studies confirmed the preventive and therapeutic efficacy of ZYSD against ischemic myocardial infarction, as evidenced by the improvement of cardiac function and the attenuation of inflammation and oxidative stress. Using network pharmacology and molecular docking, the active constituents including marker compounds of ZYSD exhibited strong binding affinity to their key targets, including AKT1 and NRF2. MD simulation further indicated the binding interaction between ZYSD components and AKT1. Western blot analysis results further verified that ZYSD regulates the TLR4/NF‐κB pathway and PI3K/AKT1/NRF2 pathway. Collectively, our findings demonstrate that ZYSD mitigates inflammation and oxidative stress, potentially through the TLR4/NF‐κB and PI3K/AKT1/NRF2 pathways, thereby providing a novel strategy for the prevention and treatment of ischemic myocardial infarction.